258 related articles for article (PubMed ID: 32601387)
1. A molecular basis for neurofibroma-associated skeletal manifestations in NF1.
Ma Y; Gross AM; Dombi E; Pemov A; Choi K; Chaney K; Rhodes SD; Angus SP; Sciaky N; Clapp DW; Ratner N; Widemann BC; Rios JJ; Elefteriou F
Genet Med; 2020 Nov; 22(11):1786-1793. PubMed ID: 32601387
[TBL] [Abstract][Full Text] [Related]
2. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma.
Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y
Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222
[No Abstract] [Full Text] [Related]
4. Increased nuclear translation of YAP might act as a potential therapeutic target for NF1-related plexiform neurofibroma.
Liu JL; You YH; Tian ZW; Xiao M; Zheng JW; Wang YA; Du Z
Int J Med Sci; 2021; 18(9):2008-2016. PubMed ID: 33850471
[TBL] [Abstract][Full Text] [Related]
5. Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage.
Jackson M; Ahmari N; Wu J; Rizvi TA; Fugate E; Kim MO; Dombi E; Arnhof H; Boehmelt G; Düchs MJ; Long CJ; Maier U; Trapani F; Hofmann MH; Ratner N
J Pharmacol Exp Ther; 2023 May; 385(2):106-116. PubMed ID: 36849412
[TBL] [Abstract][Full Text] [Related]
6. NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation.
Yu Y; Choi K; Wu J; Andreassen PR; Dexheimer PJ; Keddache M; Brems H; Spinner RJ; Cancelas JA; Martin LJ; Wallace MR; Legius E; Vogel KS; Ratner N
Acta Neuropathol; 2020 Jan; 139(1):157-174. PubMed ID: 31664505
[TBL] [Abstract][Full Text] [Related]
7. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
[TBL] [Abstract][Full Text] [Related]
8. Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.
Flint AC; Mitchell DK; Angus SP; Smith AE; Bessler W; Jiang L; Mang H; Li X; Lu Q; Rodriguez B; Sandusky GE; Masters AR; Zhang C; Dang P; Koenig J; Johnson GL; Shen W; Liu J; Aggarwal A; Donoho GP; Willard MD; Bhagwat SV; Clapp DW; Rhodes SD
Clin Cancer Res; 2023 Sep; 29(17):3438-3456. PubMed ID: 37406085
[TBL] [Abstract][Full Text] [Related]
9. Current status of MEK inhibitors in the treatment of plexiform neurofibromas.
Gross AM; Dombi E; Widemann BC
Childs Nerv Syst; 2020 Oct; 36(10):2443-2452. PubMed ID: 32607696
[TBL] [Abstract][Full Text] [Related]
10. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.
Galvin R; Watson AL; Largaespada DA; Ratner N; Osum S; Moertel CL
Curr Oncol Rep; 2021 Mar; 23(4):45. PubMed ID: 33721151
[TBL] [Abstract][Full Text] [Related]
11. Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor.
Cohen-Barak E; Toledano-Alhadef H; Danial-Farran N; Livneh I; Mwassi B; Hriesh M; Zagairy F; Gafni-Amsalem C; Bashir H; Khayat M; Warrour N; Sher O; Marom D; Postovsky S; Dujovny T; Ziv M; Shalev SA
Exp Dermatol; 2022 May; 31(5):775-780. PubMed ID: 34913528
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells.
Ferrer M; Gosline SJC; Stathis M; Zhang X; Guo X; Guha R; Ryman DA; Wallace MR; Kasch-Semenza L; Hao H; Ingersoll R; Mohr D; Thomas C; Verma S; Guinney J; Blakeley JO
Sci Data; 2018 Jun; 5():180106. PubMed ID: 29893754
[TBL] [Abstract][Full Text] [Related]
13. Head circumference and anthropometric changes and their relation to plexiform and skin neurofibromas in sporadic and familial neurofibromatosis 1 Brazilian adults: a cross-sectional study.
Basto DL; de Souza Vieira G; Andrade-Losso RM; Almeida PN; Riccardi VM; Rozza-de-Menezes RE; Cunha KS
Orphanet J Rare Dis; 2022 Sep; 17(1):341. PubMed ID: 36064430
[TBL] [Abstract][Full Text] [Related]
14. Modeling tumors of the peripheral nervous system associated with Neurofibromatosis type 1: Reprogramming plexiform neurofibroma cells.
Mazuelas H; Carrió M; Serra E
Stem Cell Res; 2020 Dec; 49():102068. PubMed ID: 33160273
[TBL] [Abstract][Full Text] [Related]
15. Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening.
Kraniak JM; Chalasani A; Wallace MR; Mattingly RR
Exp Neurol; 2018 Jan; 299(Pt B):289-298. PubMed ID: 29055717
[TBL] [Abstract][Full Text] [Related]
16. Clonal origin of tumor cells in a plexiform neurofibroma with LOH in NF1 intron 38 and in dermal neurofibromas without LOH of the NF1 gene.
Däschner K; Assum G; Eisenbarth I; Krone W; Hoffmeyer S; Wortmann S; Heymer B; Kehrer-Sawatzki H
Biochem Biophys Res Commun; 1997 May; 234(2):346-50. PubMed ID: 9177273
[TBL] [Abstract][Full Text] [Related]
17. Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.
Carrió M; Mazuelas H; Richaud-Patin Y; Gel B; Terribas E; Rosas I; Jimenez-Delgado S; Biayna J; Vendredy L; Blanco I; Castellanos E; Lázaro C; Raya Á; Serra E
Stem Cell Reports; 2019 Feb; 12(2):411-426. PubMed ID: 30713041
[TBL] [Abstract][Full Text] [Related]
18. Superimposed Mosaicism in the Form of Extremely Extended Segmental Plexiform Neurofibroma Caused by a Novel Pathogenic Variant in the NF1 Gene.
Veres K; Bene J; Hadzsiev K; Garami M; Pálla S; Happle R; Medvecz M; Szalai ZZ
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569527
[TBL] [Abstract][Full Text] [Related]
19. Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells.
Staser K; Yang FC; Clapp DW
Curr Opin Hematol; 2010 Jul; 17(4):287-93. PubMed ID: 20571392
[TBL] [Abstract][Full Text] [Related]
20. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.
Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR
Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
